BRISTOL-MYERS SQUIBB CO (1BMY.MI) Stock Fundamental Analysis
Europe - BIT:1BMY - US1101221083 - Common Stock
38.4 EUR
-1.26 (-3.18%)
1BMY gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 53 industry peers in the Pharmaceuticals industry. 1BMY has only an average score on both its financial health and profitability. 1BMY scores decently on growth, while it is valued quite cheap. This could make an interesting combination. Finally 1BMY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
1BMY had positive earnings in the past year.
1BMY had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: 1BMY reported negative net income in multiple years.
1BMY had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of 5.33%, 1BMY perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
With a decent Return On Equity value of 28.96%, 1BMY is doing good in the industry, outperforming 77.78% of the companies in the same industry.
1BMY has a Return On Invested Capital of 16.07%. This is in the better half of the industry: 1BMY outperforms 79.63% of its industry peers.
1BMY had an Average Return On Invested Capital over the past 3 years of 11.67%. This is below the industry average of 15.19%.
The 3 year average ROIC (11.67%) for 1BMY is below the current ROIC(16.07%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.33% | ||
| ROE | 28.96% | ||
| ROIC | 16.07% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)11.67%
ROIC(5y)9.83%
1.3 Margins
With a Profit Margin value of 10.58%, 1BMY perfoms like the industry average, outperforming 46.30% of the companies in the same industry.
1BMY's Operating Margin of 30.27% is fine compared to the rest of the industry. 1BMY outperforms 77.78% of its industry peers.
1BMY's Operating Margin has declined in the last couple of years.
1BMY has a Gross Margin of 73.92%. This is in the better half of the industry: 1BMY outperforms 62.96% of its industry peers.
1BMY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.27% | ||
| PM (TTM) | 10.58% | ||
| GM | 73.92% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), 1BMY is creating value.
The number of shares outstanding for 1BMY has been reduced compared to 1 year ago.
The number of shares outstanding for 1BMY has been reduced compared to 5 years ago.
The debt/assets ratio for 1BMY is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.03 indicates that 1BMY is not a great score, but indicates only limited risk for bankruptcy at the moment.
1BMY has a Altman-Z score of 2.03. This is in the lower half of the industry: 1BMY underperforms 62.96% of its industry peers.
The Debt to FCF ratio of 1BMY is 3.37, which is a good value as it means it would take 1BMY, 3.37 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.37, 1BMY is in line with its industry, outperforming 59.26% of the companies in the same industry.
A Debt/Equity ratio of 2.56 is on the high side and indicates that 1BMY has dependencies on debt financing.
With a Debt to Equity ratio value of 2.56, 1BMY is not doing good in the industry: 79.63% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.56 | ||
| Debt/FCF | 3.37 | ||
| Altman-Z | 2.03 |
ROIC/WACC2.06
WACC7.8%
2.3 Liquidity
1BMY has a Current Ratio of 1.21. This is a normal value and indicates that 1BMY is financially healthy and should not expect problems in meeting its short term obligations.
1BMY has a Current ratio of 1.21. This is comparable to the rest of the industry: 1BMY outperforms 40.74% of its industry peers.
A Quick Ratio of 1.11 indicates that 1BMY should not have too much problems paying its short term obligations.
1BMY's Quick ratio of 1.11 is fine compared to the rest of the industry. 1BMY outperforms 74.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.11 |
3. Growth
3.1 Past
1BMY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 391.24%, which is quite impressive.
1BMY shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -24.57% yearly.
1BMY shows a small growth in Revenue. In the last year, the Revenue has grown by 2.57%.
The Revenue has been growing by 13.06% on average over the past years. This is quite good.
EPS 1Y (TTM)391.24%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-29.47%
Revenue 1Y (TTM)2.57%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%0.56%
3.2 Future
The Earnings Per Share is expected to grow by 36.11% on average over the next years. This is a very strong growth
1BMY is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -4.99% yearly.
EPS Next Y477.64%
EPS Next 2Y131.04%
EPS Next 3Y73.61%
EPS Next 5Y36.11%
Revenue Next Year-1.12%
Revenue Next 2Y-4.71%
Revenue Next 3Y-3.48%
Revenue Next 5Y-4.99%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
1BMY is valuated cheaply with a Price/Earnings ratio of 6.67.
1BMY's Price/Earnings ratio is rather cheap when compared to the industry. 1BMY is cheaper than 92.59% of the companies in the same industry.
When comparing the Price/Earnings ratio of 1BMY to the average of the S&P500 Index (27.77), we can say 1BMY is valued rather cheaply.
The Price/Forward Earnings ratio is 7.37, which indicates a rather cheap valuation of 1BMY.
Compared to the rest of the industry, the Price/Forward Earnings ratio of 1BMY indicates a rather cheap valuation: 1BMY is cheaper than 90.74% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of 1BMY to the average of the S&P500 Index (23.23), we can say 1BMY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.67 | ||
| Fwd PE | 7.37 |
4.2 Price Multiples
88.89% of the companies in the same industry are more expensive than 1BMY, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, 1BMY is valued cheaper than 94.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.26 | ||
| EV/EBITDA | 6 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
1BMY's earnings are expected to grow with 73.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y131.04%
EPS Next 3Y73.61%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 5.72%, 1BMY is a good candidate for dividend investing.
1BMY's Dividend Yield is rather good when compared to the industry average which is at 3.00. 1BMY pays more dividend than 92.59% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.36, 1BMY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.72% |
5.2 History
The dividend of 1BMY is nicely growing with an annual growth rate of 11.67%!
Dividend Growth(5Y)11.67%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
98.12% of the earnings are spent on dividend by 1BMY. This is not a sustainable payout ratio.
The dividend of 1BMY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP98.12%
EPS Next 2Y131.04%
EPS Next 3Y73.61%
BIT:1BMY (10/7/2025, 7:00:00 PM)
38.4
-1.26 (-3.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners82.84%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap78.16B
Revenue(TTM)47.70B
Net Income(TTM)5.05B
Analysts67.27
Price Target44.38 (15.57%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.72% |
Yearly Dividend2.07
Dividend Growth(5Y)11.67%
DP98.12%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.2%
Min EPS beat(2)19.36%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)21.86%
Min EPS beat(4)13.54%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)17.22%
EPS beat(12)11
Avg EPS beat(12)11.73%
EPS beat(16)15
Avg EPS beat(16)9.9%
Revenue beat(2)2
Avg Revenue beat(2)5.24%
Min Revenue beat(2)3.68%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)5.13%
Min Revenue beat(4)3.68%
Max Revenue beat(4)6.79%
Revenue beat(8)7
Avg Revenue beat(8)3.53%
Revenue beat(12)8
Avg Revenue beat(12)1.72%
Revenue beat(16)10
Avg Revenue beat(16)1.44%
PT rev (1m)-3.96%
PT rev (3m)-9.57%
EPS NQ rev (1m)-5.08%
EPS NQ rev (3m)-7.02%
EPS NY rev (1m)0.08%
EPS NY rev (3m)-5.25%
Revenue NQ rev (1m)0.29%
Revenue NQ rev (3m)1.21%
Revenue NY rev (1m)0.15%
Revenue NY rev (3m)2.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.67 | ||
| Fwd PE | 7.37 | ||
| P/S | 1.91 | ||
| P/FCF | 6.26 | ||
| P/OCF | 5.74 | ||
| P/B | 5.24 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6 |
EPS(TTM)5.76
EY15%
EPS(NY)5.21
Fwd EY13.57%
FCF(TTM)6.13
FCFY15.97%
OCF(TTM)6.69
OCFY17.42%
SpS20.06
BVpS7.33
TBVpS-10.82
PEG (NY)0.01
PEG (5Y)N/A
Graham Number30.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.33% | ||
| ROE | 28.96% | ||
| ROCE | 21.51% | ||
| ROIC | 16.07% | ||
| ROICexc | 20.14% | ||
| ROICexgc | 101.89% | ||
| OM | 30.27% | ||
| PM (TTM) | 10.58% | ||
| GM | 73.92% | ||
| FCFM | 30.56% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)11.67%
ROIC(5y)9.83%
ROICexc(3y)13.73%
ROICexc(5y)11.71%
ROICexgc(3y)74.95%
ROICexgc(5y)76.74%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexgc growth 3Y-16.88%
ROICexgc growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score7
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.56 | ||
| Debt/FCF | 3.37 | ||
| Debt/EBITDA | 2.14 | ||
| Cap/Depr | 20.37% | ||
| Cap/Sales | 2.77% | ||
| Interest Coverage | 6.99 | ||
| Cash Conversion | 75.95% | ||
| Profit Quality | 288.73% | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.11 | ||
| Altman-Z | 2.03 |
F-Score7
WACC7.8%
ROIC/WACC2.06
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)391.24%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-29.47%
EPS Next Y477.64%
EPS Next 2Y131.04%
EPS Next 3Y73.61%
EPS Next 5Y36.11%
Revenue 1Y (TTM)2.57%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%0.56%
Revenue Next Year-1.12%
Revenue Next 2Y-4.71%
Revenue Next 3Y-3.48%
Revenue Next 5Y-4.99%
EBIT growth 1Y30.41%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year263.82%
EBIT Next 3Y49.42%
EBIT Next 5Y23.71%
FCF growth 1Y35.99%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y34.19%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%